Evidence map›Paper›PMID 39580469›Full record

ArticleMolecular cancer2024

Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinoma.

Yi-Feng Ren, Qiong Ma, Xiao Zeng, Chun-Xia Huang, Jia-Li Ren, Fang Li, Jia-Jing Tong, Jia-Wei He, Yang Zhong, Shi-Yan Tan and 11 more

Abstract read
In one paragraph

Article in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. IL-17D reprograms CD93Cellular & molecular immunology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yi-Feng Ren *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Qiong Ma *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Xiao Zeng *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Chun-Xia HuangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Jia-Li RenLC-Bio Technologies (Hangzhou) CO., LTD, Hangzhou, 310018, Zhejiang Province, China.
Fang LiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Jia-Jing TongLC-Bio Technologies (Hangzhou) CO., LTD, Hangzhou, 310018, Zhejiang Province, China.
Jia-Wei HeHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Yang ZhongHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Shi-Yan TanHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Hua JiangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Long-Fei ZhangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Heng-Zhou LaiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Ping XiaoDepartment of Thoracic Surgery, School of Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610042, Sichuan Province, China.
Xiang ZhuangDepartment of Thoracic Surgery, School of Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610042, Sichuan Province, China.
Peng WuLC-Bio Technologies (Hangzhou) CO., LTD, Hangzhou, 310018, Zhejiang Province, China.
Li-Ting YouTCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Wei ShiDepartment of Anesthesiology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.
Xi FuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China.
Chuan ZhengHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China. zhengchuan@cdutcm.edu.cn.
Feng-Ming YouHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan Province, China. yfmdoc@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiographically, ground-glass nodules (GGN) and part-solid nodules (PSN) in lung adenocarcinoma (LUAD) have significant heterogeneity in their clinical manifestations, biological characteristics, and prognosis. This study aimed to explore the heterogeneity of LUAD in different radiological phenotypes and associated factors influencing tumor evolution.

methodsWe performed single-cell RNA sequencing (scRNA-seq) on tumor tissues from eight and seven cases of GGN- and PSN-LUAD, respectively, at different disease stages, including minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (IAC), and metastatic lung cancer (MLC). Additionally, we analyzed adjacent normal tissues from four cases. Immunohistochemistry, multiplex immunofluorescence, and external scRNA-seq data were employed to confirm the expression of signature genes as well as the distribution patterns of CXCL9 + TAMs and TREM2 + TAMs. A LUAD mouse model was generated using gene editing, organoid culture, and orthotopic transplantation techniques, and comprehensive analyses such as histopathology, RNA sequencing, and Western blotting were performed to validate key pathways.

resultsDiverse cellular compositions were observed in the tumor microenvironment (TME) during GGN- and PSN-LUAD invasion and metastasis. Notably, CXCL9 + and TREM2 + tumor-associated macrophages (TAMs) exhibited the most significant enrichment changes. It was found that GGN-LUAD exhibited a stronger immune response than PSN-LUAD, with increased interaction between CXCL9 + TAMs and CD8 + tissue-resident memory T cells during invasion stage (MIA-IAC). Conversely, greater interactions between TREM2 + TAMs and tumor cells were observed in PSN-LUAD during the MLC stage. Additionally, TREM2 + TAMs were found to differentiate into TREM2 + /SPP1 + and TREM2 + /SPP1- TAMs at different stages, which promotes tumor progression. This study also emphasizes that during the transdifferentiation process of GGN- and PSN-LUAD, IFN-γ activates the STAT1 signaling pathway to regulate the activation of CXCL9 + TAMs, and further recruiting CD8 + Trm cells and activating T cells through MHC class I antigen presentation. The role of the IFN-γ/STAT1 pathway in the occurrence and development of LUAD was further validated by animal experiments.

conclusionsOur findings offer a potential therapeutic strategy to maintain a dynamic balance within the TME and improve the immunotherapy efficacy by modulating the relative proportions and functional states of CXCL9 + TAMs and TREM2 + TAMs.

Indexed as

Adenocarcinoma of LungLung NeoplasmsSingle-Cell AnalysisTumor MicroenvironmentAnimalsBiomarkers, TumorChemokine CXCL9Disease Models, AnimalFemaleGene Expression Regulation, NeoplasticHumansMaleMembrane GlycoproteinsMiceMiddle AgedNeoplasm InvasivenessBiomarkers, TumorChemokine CXCL9CXCL9 protein, humanMembrane GlycoproteinsReceptors, ImmunologicSTAT1 protein, humanSTAT1 Transcription FactorTREM2 protein, humanCXCL9Lung adenocarcinomaPulmonary noduleSingle-cell RNA sequencingSPP1TREM2Tumor-associated macrophageTumor microenvironment

Identifiers

PMID39580469
PMCPMC11585206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.